Blockchain Registration Transaction Record

Cardiol Therapeutics Reports Positive Results from Phase II MAvERIC-Pilot Study

Cardiol Therapeutics reports positive topline results from Phase II MAvERIC-Pilot study, demonstrating potential breakthrough in recurrent pericarditis treatment.

The groundbreaking results from Cardiol Therapeutics' Phase II study could revolutionize the treatment of recurrent pericarditis, providing a non-immunosuppressive therapeutic option for patients. This announcement signifies a potential breakthrough in addressing the critical need for effective treatments for recurrent pericarditis, offering hope to thousands of patients and potentially reducing the economic burden of healthcare costs.